Explore Neural Mechanism of Obsessive-Compulsive Disorder (OCD) by Intervention of Repetitive Transcranial Magnetic Stimulation With Symptom Provocation
The purpose of this study is to investigate the differences in therapeutic efficacy of different deep Transcranial Magnetic Stimulation (deep TMS) treatment coils and different brain stimulation targets on obsessive-compulsive symptoms, and to explore the neural mechanisms of obsessive-compulsive disorder using functional neuroimaging analysis.
Inclusion Criteria:
Adults aged 18-65 years. Patients diagnosed with obsessive-compulsive disorder according to DSM-5 criteria.
- Study Design: Double-blind, randomized assignment.
Number of Participants:
Sham group: 32 participants Active H7 group: 32 participants Active H1 group: 32 participants Total: 96 participants
Study Procedures:
- Participant Screening and Baseline Assessment (Week 0) Determine eligibility for enrollment, including diagnostic confirmation, symptom assessment, screening for contraindications, and whether the participant has previously experienced adverse effects following TMS treatment. Participants with high suicide risk within the past year will be excluded.
Develop a personalized symptom provocation procedure for obsessive-compulsive symptoms.
Complete baseline symptom severity assessments and brain positron emission tomography/magnetic resonance imaging (PET/MRI). Participants with structural brain abnormalities will be excluded.
Participants will be randomly assigned (1:1:1) into three groups, with a planned total enrollment of 96 participants.
Participants currently taking medication may continue their existing regimen, but no medication changes will be allowed during the study period.
- Treatment Phase (Week 1 to Week 6; duration: 6 weeks) Before each TMS session, participants will remove their shoes and socks, rest both hands flat on their thighs, keep their eyes looking straight ahead, and undergo measurement of resting motor threshold (RMT).
Approximately 3-5 minutes before each TMS session, trained personnel with Exposure and Response Prevention (ERP) experience will assist participants in symptom provocation and record the participant's subjective level of distress.
The deep TMS treatment schedule consists of five sessions per week, one session per day, for six consecutive weeks. Adverse effects will be assessed and monitored at each session.
After completing the first treatment session, participants will be asked to guess which group they were assigned to, in order to evaluate the effect of treatment expectations on outcomes.
Symptom severity interviews will be conducted every two weeks.
- Post-treatment Assessment and Follow-up (Week 7 and after; duration: 2 weeks, then 6 months later) Within one week after completion of the deep TMS treatment course (within Week 7), participants will undergo follow-up brain PET/MRI.
At the end of Week 8 (two weeks after treatment completion), symptom severity will be reassessed. Subsequent treatment plans will be discussed with participants, and outpatient follow-up will be arranged within six months.
Subsequent treatment options may include cognitive behavioral therapy, pharmacotherapy, and figure-8 rTMS.
Statistical Analysis
- Expected Outcomes:
The H7 coil may improve obsessive-compulsive symptoms. Both the H7 and H1 coils may improve mood symptoms.
- Descriptive and Inferential Statistics: Analysis of covariance (ANCOVA) will be used to compare differences among the three groups in Montgomery-Asberg Depression Rating Scale (MADRS), Yale-Brown obsessive compulsive scale (Y-BOCS), Hamilton Anxiety Scale (HAM-A), Hamilton Depression Scale (HDRS), and Clinical Global Impression (CGI-S) scores.
The percentage of responders (% responders) will be calculated and compared among groups.
Repeated-measures ANOVA will be used to examine within-group and between-group differences in symptom improvement before and after deep TMS treatment.
Pearson correlation analysis will be used to assess the association between symptom improvement and changes observed in PET/MRI neuroimaging measures.
- PET/MRI Neuroimaging Analysis: Functional MRI analyses will include ROI-to-ROI functional connectivity and seed-based functional connectivity analyses.
Changes in PET glucose uptake within specific regions of interest (ROIs) will also be examined to evaluate alterations in neural networks and brain function before and after deep TMS treatment.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Cheng-Ta Li
- 电话号码:886-2-55704055
- 邮箱:ctli0420@gmail.com
研究联系人备份
- 姓名:Chia-Min Huang
- 邮箱:psygrace1@gmail.com
学习地点
-
-
-
Taipei、台湾
- 招聘中
- Taipei Veterans General Hospital
-
接触:
- Cheng-Ta Li
- 电话号码:886-2-55704055
- 邮箱:ctli0420@gmail.com
-
接触:
- Chia-Min Huang
- 邮箱:psygrace1@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Adults aged 18-65 years.
- Diagnosis of obsessive-compulsive disorder according to DSM-5 criteria. Treatment resistance (i.e., inadequate response to pharmacological or non-pharmacological treatments) is not required.
- Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥ 14, indicating at least mild to moderate symptom severity.
Exclusion Criteria:
- Diagnosis of schizophrenia, organic psychotic disorder, bipolar disorder, alcohol use disorder, or substance use disorder.
- High suicide risk within the past year.
- Presence of significant medical or surgical conditions in an active phase.
- History of, or planned, neurosurgical procedures, or presence of metallic implants in the brain or body (e.g., neurostimulators or cardiac pacemakers).
- Structural brain abnormalities (e.g., brain tumor or arteriovenous malformation) or neurological disorders (e.g., meningitis, encephalitis, stroke, or epilepsy).
- Pregnant women.
- Inability to tolerate PET/MRI examination due to claustrophobia or severe anxiety in confined spaces.
- Any other conditions that may impair study compliance, including inability to cooperate, failure to provide informed consent, or other investigator-determined ineligibility after screening.
- Use of medications that may increase seizure risk or suicide risk (e.g., certain antidepressants or antipsychotics).
- Known allergy to 18F-FDG (18F-2-Fluoro-2-DeoxyGlucose).
- History of adverse reaction to TMS or allergy to the positioning cap.
- Presence of metallic objects within approximately 30 cm of the cranial region (within the stimulation coil area).
- Prior or current treatment with electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Active H7 coil stimulation
|
Sham dTMS Participants will receive sham deep TMS using a sham coil. H7 dTMS Participants will receive active deep TMS using the H7 coil. H1 dTMS Participants will receive active deep TMS using the H1 coil. |
|
假比较器:Sham stimulation group
|
Sham dTMS Participants will receive sham deep TMS using a sham coil. H7 dTMS Participants will receive active deep TMS using the H7 coil. H1 dTMS Participants will receive active deep TMS using the H1 coil. |
|
实验性的:Active H1 coil group
|
Sham dTMS Participants will receive sham deep TMS using a sham coil. H7 dTMS Participants will receive active deep TMS using the H7 coil. H1 dTMS Participants will receive active deep TMS using the H1 coil. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
the percentage changes in Y-BOCS scores after treatments
大体时间:the 6-week and 8-week
|
Two time-spans are assessed: (a) from baseline (Week 0, W0) to posttreatment (Week 6, W6), and (b) from baseline (W0) to the 2-week follow-up (Week 8, W8). The percentage changes in Y-BOCS scores will be calculated as follows:
|
the 6-week and 8-week
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.